Test ID: IGFGP    
Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein 3 Growth Panel, Serum

Method Description Describes how the test is performed and provides a method-specific reference

Insulin-Like Growth Factor 1:

Stable isotope labeled internal standard is added to patient samples. Insulin-like growth factor 1 (IGF1) is then extracted by selective precipitation. The extracted samples are analyzed by liquid chromatography-mass spectrometry. This is a laboratory-developed MS test, calibrated against the First World Health Organization International standard for IGF1 (02/254).(Unpublished Mayo method)


Insulin-Like Growth Factor-Binding Protein 3:

The IMMULITE 2000 IGFBP3 (insulin-like growth factor-binding protein 3) is a solid-phase, enzyme-linked chemiluminescent immunoassay based on murine monoclonal antibodies. The patient sample and alkaline phosphatase-conjugated anti-IGFBP3 antibodies are simultaneously incubated with an antibody-coated bead. During this time, IGFBP3 in the sample forms an antibody sandwich complex that binds to the streptavidin on the bead. Unbound enzyme conjugate is then removed by washing, after which substrate is added. The chemiluminescent substrate, a phosphate ester of adamantyl dioxetane, undergoes hydrolysis in the presence of alkaline phosphatase to yield an unstable intermediate. The continuous production of this intermediate results in the sustained emission of light. The photon output is directly proportional to the concentration of IGFBP-3 in the sample.(Package insert: IMMULITE 2000 IGFBP-3. Siemens Healthcare Diagnostics; PIL2KGB-15. 03/2018)

PDF Report Indicates whether the report includes an additional document with charts, images or other enriched information


Day(s) Performed Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

IGFB3: Monday through Friday, Saturday

IGFMS: Monday through Friday, Sunday

Report Available The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

2 to 4 days

Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

14 days

Performing Laboratory Location Indicates the location of the laboratory that performs the test